🧠 Clinical Context

Patients over 65 undergoing inpatient surgery face unique risks. Cognitive impairment, frailty, and increased vulnerability to delirium demand a proactive and nuanced approach to anesthesia and postoperative care.

🔍 Preoperative Priorities

• Age ≥65 and inpatient status should automatically trigger a frailty and cognitive assessment
• Engage a multidisciplinary team early—geriatrics, anesthesia, surgery, and nursing

🛌 Postoperative Delirium: A Common Pitfall

• Use dexmedetomidine in the PACU or ICU setting for sedation/delirium prevention
• Avoid these culprits:
  • Benzodiazepines
  • Antipsychotics
  • Anticholinergics
  • Ketamine
  • Corticosteroids
  • Gabapentin

💡 Practical Strategy

• Optimize environment: quiet, well-lit rooms with clocks and calendars
• Encourage mobility and family engagement
• Hydrate, monitor electrolytes, and manage pain thoughtfully
• Avoid over-sedation and unnecessary polypharmacy

🧩 Clinical Takeaway

Older adults need tailored perioperative management. Screening for frailty and cognition is just as important as lab work and EKGs. Avoid high-risk meds, plan for delirium prevention, and build a team around the patient.

🎯 When it comes to older surgical patients: less is more, and team-based care is everything.

Key Reference: Sieber F et al. 2025 ASA Practice Advisory for Perioperative Care of Older Adults. Anesthesiology. 2025 Jan;142(1):22–51. PMID: 39655991

🧠 Clinical Context

Hydrochlorothiazide (HCTZ) vs. Chlorthalidone—a classic cardio debate! ALHAT once hinted at chlorthalidone’s superiority, but did a modern head-to-head trial confirm that? Let's break it down.

🧪 Study Snapshot: The HEADS-UP Trial

• Design: Randomized, head-to-head trial
• Population: ~14,000 patients, age ≥65, already on HCTZ 25–50 mg + 1–2 antihypertensives
• Prior CV disease: 15% had MI, stroke, or HF
• Groups:
  • Continue HCTZ
  • Switch to Chlorthalidone 12.5–25 mg daily
• Follow-up: Median 2.4 years

📈 Outcomes

• Primary endpoint: Composite of MI, stroke, HF, urgent revascularization, or non-cancer death
  → Occurred in 10% of both groups
• BP Control: No significant difference
• Hypokalemia:
  • Chlorthalidone: 4.4%
  • HCTZ: 6.0%

💡 What About CKD?

• 23% had GFR <60 at baseline, but…
• No strong data on severely reduced renal function for HCTZ
• In a 12-week placebo-controlled study, chlorthalidone lowered BP in GFR 15–30, but HCTZ didn’t have similar data
• Still, in randomized trials: no difference in mortality or cardiovascular outcomes

⚠️ Surprises & Caveats

• Despite historical bias toward chlorthalidone, outcomes and BP control were equivalent
• Hypokalemia was actually slightly lower with chlorthalidone
• More robust data is still needed for advanced CKD patients

🧩 Clinical Takeaway

Despite all the hype, chlorthalidone isn’t clearly superior. In practice, both meds perform similarly for hypertension control and cardiovascular outcomes in older adults. But if your patient has significantly impaired renal function, chlorthalidone may edge ahead—at least for now.

💬 Bottom line? Choose the thiazide based on patient profile, tolerance, and renal function—not legacy dogma.

🧠 Clinical Context

GLP-1 receptor agonists have taken center stage for both type 2 diabetes and obesity management, but their gastric side effects are giving anesthesiologists pause. The ASA's recent guidance recommends holding these agents before surgery to reduce risks of gastroparesis, regurgitation, and pulmonary aspiration.

🔬 ASA Guidelines Overview

• Daily Dosing? Hold on the day of surgery
• Weekly Dosing? Hold one week prior
• If asymptomatic and held as above? Proceed as usual

⚠️ But Here’s the Controversy

• There’s no strong evidence that holding GLP-1s as recommended reliably reduces gastric content risk.
• Recent endoscopy studies show no correlation between hold duration and gastric content retention.
• Gastroparesis risk may persist despite withholding the drug, especially in patients with:
  • Diabetes
  • Obesity
  • Opioid use
  • Alcohol, marijuana, or TCA use

🧪 What We Do Know

• Peak delay in gastric emptying appears within the first 12 weeks of therapy.
• Normalization of gastric motility might require holding meds for 5+ half-lives—often impractical.
• Meanwhile, GLP-1s improve glycemic control and may reduce post-op MACE (Major Adverse Cardiac Events).

🧭 Pragmatic Recommendations

• All GLP-1 patients should be considered at elevated aspiration risk, regardless of symptom status or hold duration.
• Use pre-op gastric ultrasound to assess contents.
• Plan anesthesia accordingly:
  • Airway protection
  • Rapid sequence induction
  • Appropriate surgical location

🍽️ Fasting Guidelines? A Gray Area

ASA’s updated fasting guideline (2023) applies to healthy patients without reflux, obesity, diabetes, or delayed emptying—aka, not your typical GLP-1 patient.

Recommendation: Modify fasting guidelines based on judgment. Don’t follow enhanced recovery protocols blindly.

🧩 Clinical Takeaway

Don’t assume that simply holding a GLP-1 agonist clears the gut. Evidence is lacking. Every GLP-1 patient should be approached with caution:

• Assume delayed gastric emptying
• Use tools like ultrasound for verification
• Customize fasting and airway protocols

🔍 Until we have more data, err on the side of protecting your patient’s airway—not just the guideline.

Key Reference: Ushakumari DS, Sladen RN. ASA Consensus-based Guidance. Anesthesiology. 2024 Feb;140(2):346–348. PMID: 37982170

🧠 Clinical Context

DOACs (Direct Oral Anticoagulants) have revolutionized anticoagulation—goodbye routine INRs, hello convenience. But while they’ve made our lives easier, they’re not always a fit for every scenario. Here's how to navigate the DOAC jungle.

✅ When DOACs Are Preferred

• Venous Thromboembolism (VTE)
• Atrial Fibrillation
  • ⚠️ Exclude patients with:
    • Mechanical heart valves
    • Rheumatic mitral valve disease
       (That’s why cardiologists note “non-rheumatic” AF in their documentation—treatment plan hinges on it.)

⛔ When DOACs Are a No-Go

• Mechanical Heart Valves → Warfarin only
• Rheumatic AF → Warfarin still rules
• Thrombotic Antiphospholipid Syndrome → Warfarin
• Transcatheter Aortic Valve Replacement (TAVR) → Antiplatelet therapy
• Embolic Stroke of Undetermined Source → Antiplatelets preferred

🤔 The Gray Zone: Uncertain Use Cases

These aren’t absolute yes or no. Instead, cue shared decision-making and expert input:

• Pregnancy
  • No strong evidence yet; avoid unless discussed with OB and hematology.
• End-Stage Renal Disease (ESRD)
  • Initially excluded from DOAC trials.
  • Some are doing well, but still a case-by-case basis.
• Others That Require Discussion:
  • Left Ventricular Thrombus
  • Catheter-Associated DVT
  • Splanchnic Vein Thrombosis
  • Cerebral Venous Thrombosis

🧩 Clinical Takeaway

DOACs are game-changers—but they’re not plug-and-play for everyone. For classic AF and VTE? Go for it. For valves, rheumatic disease, or complex syndromes? Tread carefully. And when in doubt, involve the patient in the decision.

🎯 Bottom line: Not every clot deserves a DOAC—some still want warfarin or a platelet plan.

Let me know when you're ready for the next one!

🧠 Clinical Context:

You're prepping a patient for non-cardiac surgery—what's their cardiovascular risk? Turns out, it’s not always about echo reports or cath results. It starts with a stairs test (sort of).

• Duke Activity Status Index (DASI) and METs >4 can tell you if the heart's got enough reserve.
  • 🚶‍♂️ “Can you walk up a flight of stairs without gasping?” If yes, you’re likely good to go!
• If functional status is poor or unknown, consider labs:
  • BNP, pro-BNP, or troponin — but evidence is weak.
  • Elevated? Time to huddle with a multidisciplinary team (or at least buy time for the patient and lawyer to meet).

🧪 Risk Tools, Not Rituals:

• Stress testing isn’t reflexively helpful anymore.
  • Reserved for high-risk anatomy or major ischemia concerns.
  • Studies show no outcome improvement in most cases.
  • Important caveat: those with severe CAD were excluded from trials!

🧊 Meds to Pause:

• SGLT2 Inhibitors (dapagliflozin, empagliflozin):
  🔴 Stop 3–4 days pre-op to avoid euglycemic ketoacidosis.
• GLP-1 Agonists:
  ⏸️ Hold 1 week before due to risk of delayed gastric emptying, aspiration, and nausea under anesthesia.

🫀 Post-op Cardiac Surveillance:

• Watch for MINS – Myocardial Injury after Noncardiac Surgery
  • Troponin trending may help spot silent ischemia post-op.
  • Elevated levels? 🧠 Consider further cardio eval, especially in high-risk patients.

🧩 Clinical Takeaway:

Modern pre-op cardiac clearance is about functional fitness, thoughtful labs, and smart medication pauses. Don’t just tick boxes—evaluate risk in context. And yes, if grandma can climb stairs without wheezing, she might just be ready for her hip replacement.

🧠 Trial:

DOAC started at 3 days vs 8–14 days post-stroke in AF patients.

📊 Results:

No ↑ bleeding.

No ↑ ischemic events.

🧩 Clinical Takeaway:

Safe to start within 4 days in mild to moderate stroke.

Still tailor based on infarct size and bleeding risk.

🧪 Study:

Vitamin K2 (180 mcg) reduced nocturnal leg cramps in elderly.

📉 Results:

Cramps/week ↓ from 3.6 → ~1 over 8 weeks.

Safe and well-tolerated.

🧩 Clinical Takeaway:

Consider a K2 trial in patients with chronic cramps — especially if sleep-disrupting.

Avoid in patients on warfarin.

🧪 Study:

TXA within 2 hrs of ICH did not reduce hematoma expansion.

No benefit in functional outcome or mortality.

⚠️ Note:

Slight ↑ in thromboembolic events (3% vs 1%).

🧩 Clinical Takeaway:

No routine use for TXA in spontaneous ICH.

Still potential niche use in select trauma cases.

🧠 Study:

Compared transfusion thresholds of Hgb <8 vs <10 in subarachnoid hemorrhage.

📊 Findings:

No difference in modified Rankin Score at 12 months.

Fewer transfusions, fewer complications in <8 group.

🧩 Clinical Takeaway:

Restrictive transfusion strategy is safe in neuro ICU.

Less exposure = better outcomes.

🧪 Trials:

RESHAPE-HF2: ↓ HF hospitalizations with transcatheter edge-to-edge repair vs medical therapy.

MATTR: Transcatheter approach non-inferior to surgical repair.

🧩 Clinical Takeaway:

Game-changing for patients too high risk for surgery.

Less peri-op risk, faster recovery — mitral repair is heading the way of TAVR.

💊 Study:

SURMOUNT-HF trial — patients with obesity and HFpEF.

Tirzepatide = ↓ HF hospitalizations and ↑ quality of life.

📈 Benefits:

Significant weight loss.

Better metabolic profiles.

GI side effects: ~6% (nausea, diarrhea).

🧩 Clinical Takeaway:

A major contender for cardio-metabolic syndrome with HFpEF.

More than just a diabetes or weight-loss drug.

🧪 Study:

Patients ≥55 with no relapses in 5 yrs and no new lesions in 3 yrs may stop disease-modifying therapy (DMT).

No significant difference in disability progression.

🧩 Clinical Takeaway:

De-escalation strategy in stable MS may reduce cost and side effects.

Still requires close neurology follow-up.

🧠 Clinical Tool:

Spot urine sodium 2 hours after IV loop diuretic.

If <50–70 mmol/L → inadequate response.

Consider doubling dose or switching loop agents.

💡 Tips:

Also assess urine output in first 6 hours (<100–150 mL/hr = poor response).

Less helpful after 24 hrs or in chronic diuretic users.

🧩 Clinical Takeaway:

Fast, practical guide to assess diuretic effectiveness in acute decompensated HF.

🧪 Key Findings:

Cohort study: SGLT2 inhibitors led to significantly lower rates of nephrolithiasis compared to GLP-1 RAs.

Mechanism: increased urinary flow and uric acid excretion.

🔢 Stats:

NNT = 20 for prevention.

NNT = 5 for recurrent stone formers.

🧩 Clinical Takeaway:

Another bonus benefit of SGLT2 inhibitors.

May sway decision in diabetics prone to stones.

HCTZ no longer holds the same weight in stone prevention.

🧪 Key Insights:

Observational data links semaglutide (GLP-1 RA) to increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Incidence: ~9–15 cases per 100,000 patient-years.

Possible mechanism: GLP-1 receptors in optic nerve ganglion cells.

No proven causality yet — retrospective study only.

🧩 Clinical Takeaway:

Risk remains very low.

Discuss with patients who have eye disease or prior NAION before initiating therapy.

🧪 VOYAGER-PAD Trial:

Patients with PAD post lower extremity revascularization.

Rivaroxaban 2.5 mg BID + aspirin vs aspirin alone.

📈 Results:

↓ Major Adverse CV Events (MACE).

↓ Major Adverse Limb Events (MALE).

Modest ↑ in bleeding — no ↑ in fatal bleeds.

🧩 Clinical Takeaway:

Now guideline-endorsed for symptomatic PAD post-intervention.

Risk-benefit conversation needed in high-bleed-risk patients.

🧠 Problem:

RLS causes chronic sleep disruption, often worsens in hospital or peri-op settings.

💊 Management:

First-line: Gabapentin or Pregabalin (per American Academy of Sleep Medicine).

Avoid long-term dopamine agonists — cause augmentation and impulse control disorders.

🩸 Bonus Tip:

Check ferritin — keep it >75 ng/mL.

Oral or IV iron can help symptom control.

🧩 Clinical Takeaway:

Treat aggressively; it’s more than “just annoying.”

Avoid benzos and older agents unless no better option.

🧪 Study:

Retrospective look at patients with intracranial hemorrhage (ICH) on warfarin for mechanical valves.

Followed for stroke, rebleed, mortality.

📈 Findings:

Only 2 strokes in first 7 days after stopping warfarin.

Most resumed warfarin around day 7 with low rebleed risk.

⚠️ Exclusions:

Massive bleeds, unstable patients, large hematomas may require longer delay.

🧩 Clinical Takeaway:

Restarting warfarin at 7 days appears safe in stable patients.

Still a team-based call — include cardiology, neurology, neurosurgery.

📊 What It Is:

A modern CV risk estimator developed from 2.3 million-person dataset.

Replaces outdated ASCVD calculator (based on 25k).

🧠 Features:

Adds BMI, GFR, A1C, and zip code.

Omits race — more equitable.

Outputs risk of heart disease, stroke, heart failure.

⚠️ Caveats:

Generally gives lower risk estimates vs ASCVD.

May reduce statin overuse, but some feel it's too conservative.

🧩 Clinical Takeaway:

Helpful in primary prevention — especially borderline cases.

Use side-by-side with ASCVD for now until guidelines update.

🧪 The EPOC Trial:

Compared FLOT chemotherapy alone vs chemo + radiation before surgery in localized esophageal/gastroesophageal adenocarcinoma.

📈 Findings:

FLOT alone led to better 3-year progression-free survival: 51.6% vs 35%.

No survival benefit from adding radiation.

Patients receiving FLOT alone had fewer complications, improved tolerance, and less treatment-related morbidity.

🧩 Clinical Takeaway:

For operable esophageal adenocarcinoma, skip the radiation if you're doing full-dose chemo.

Less burden for patients, especially elderly or frail.

🧠 Surprising contender:

OA is not just wear-and-tear — there's an inflammatory phenotype.

🧪 Trial:

MTX 10–25 mg/week in knee OA with persistent pain.

Significant ↓ pain and improved function vs placebo.

⚠️ Side Effects:

GI upset, mouth ulcers, fatigue.

Hepatotoxicity, myelosuppression, pulmonary fibrosis (rare).

Always co-prescribe folic acid.

🧩 Clinical Takeaway:

Consider in refractory OA when NSAIDs, injections, and PT have failed.

Especially useful when opioids are not an option.

🧠 Historical practice:

Pre-load clopidogrel (or ticagrelor) before cath.

Rationale: reduce thrombotic burden prior to PCI.

🧪 New Data:

Large observational study: 100k+ NSTEMI patients.

No benefit in MI or death with pretreatment.

Longer LOS, delayed CABG in pre-treated patients.

🧩 Clinical Takeaway:

Defer P2Y12 until coronary anatomy is known — especially if CABG is on the table.

If PCI is clearly planned and delay expected — preloading may still be reasonable.

🧠 Problem:

80% of menopausal women suffer from vasomotor symptoms (hot flashes, night sweats).

Many can't take hormone therapy (VTE, CAD, breast CA).

💊 Fezolinetant:

NK3 receptor antagonist — first in class.

Reduces frequency and intensity of hot flashes.

Safe in patients who can’t take estrogen.

⚠️ Side Effects:

GI symptoms, transaminitis.

Requires liver function monitoring.

🧩 Clinical Takeaway:

A breakthrough for non-hormonal menopause management.

Ideal for patients at high risk or contraindications to HRT.

🧠 Core Concept:

Cerebral perfusion pressure (CPP) = MAP – ICP.

Normal ICP = ~10 mmHg; threshold for concern >20 mmHg.

🧰 Management Strategies:

Elevate head of bed (30°), ensure neck is midline.

3% hypertonic saline preferred over mannitol in AKI.

Short-term hyperventilation (↓ PaCO₂ → vasoconstriction).

Consider sedation or decompressive craniectomy in refractory cases.

External ventricular drain (EVD) for CSF removal and monitoring.

🧩 Clinical Takeaway:

Managing ICP is about protecting perfusion.

Monitor trends closely — especially in trauma, hemorrhage, hepatic encephalopathy.

🧠 Context:

Rising rates of carbapenem-resistant gram-negatives, especially those producing MBLs like NDM, VIM.

💊 Drug Combo:

Aztreonam + Avibactam = a lifeline for metallo-beta-lactamase (MBL) producers.

FDA-approved for:

Complicated intra-abdominal infections (with metronidazole).

Hospital-acquired and ventilator-associated pneumonias (HAP/VAP).

🧩 Clinical Takeaway:

Reserved for pan-resistant infections; not a first-line agent.

ID consult required in most hospitals due to high cost and restricted use.

This is your last-resort ammo — know when to reach for it.

🧠 Background:

RSV causes significant morbidity/mortality in older adults.

Previously considered a pediatric virus only.

📈 Epidemiology:

Hospitalization rate:

91/100,000 (ages 64–74).

738/100,000 in assisted living patients.

💉 Vaccine Update:

CDC now recommends RSV vaccine for:

All ≥75 years old.

60–74 years with chronic conditions (lung, kidney, diabetes with organ damage).

Efficacy: 71–80%, wanes to ~50% by 19 months.

⚠️ Considerations:

Possible risk of Guillain-Barré — ongoing surveillance.

Only one dose needed (no boost from second shot yet).

🧩 Clinical Takeaway:

Strongly recommend for frail seniors and those in communal living.

Shared decision-making still advised for those age 60–74.

🧠 Clinical Context

We’ve long been taught to stop metformin once GFR drops below 30 due to concerns about lactic acidosis. But what if—just maybe—some patients might actually do better by continuing it? Enter a large-scale Scottish national database review that turned this dogma on its head.

🧪 Study Highlights

• Design: Retrospective analysis of a national database in Scotland
• Population: Patients with Stage 4 and 5 CKD (GFR <30 mL/min) who continued metformin for over 6 months despite guidelines
• Group Division:
  • Continued metformin past GFR <30
  • Stopped metformin upon reaching GFR <30

📈 Outcomes

• Mortality:
  • Patients who continued metformin had lower 3-year all-cause mortality compared to those who stopped
• Cause of Death:
  • Leading causes in both groups: cancer, respiratory disease, cardiovascular events
  • Interestingly, respiratory deaths were significantly lower in those who stayed on metformin
• CV Events: No significant difference in major adverse cardiovascular outcomes between the groups

⚠️ Caveats

• Not a randomized trial — many possible confounders
• Nearly half of those continuing metformin eventually stopped due to provider decision or follow-up
• Mechanism for fewer respiratory deaths is unknown — could be unrelated or due to unmeasured factors

🧩 Clinical Takeaway

This accidental natural experiment suggests we might be a bit too strict with our GFR <30 cutoff. While lactic acidosis risk is real, the data hints that patients with stable CKD might tolerate metformin better than previously thought.

💡 Time to rethink? Maybe. But we still need prospective trials to safely redraw the lines. For now, this is not a green light, but definitely a yellow one.

Data Source: Scottish National Database, observational cohort

🧠 Clinical Problem:

HFpEF (Heart Failure with Preserved EF) has lacked effective, proven therapies.

Finerenone (non-steroidal MRA) offers new hope.

🧪 FINEARTS-HF Trial:

6,000+ patients with EF ≥40%, followed for ~32 months.

Compared Finerenone vs placebo.

📈 Results:

↓ Heart failure hospitalization significantly.

No significant reduction in CV mortality.

Hyperkalemia: 9.7% (Finerenone) vs 4.2% (Placebo).

🧩 Clinical Takeaway:

May offer benefit for HFpEF — especially if SGLT2i also used.

Expensive; Spironolactone may be a lower-cost alternative with similar benefit.

Important addition to the limited HFpEF toolbox.

🧠 Clinical Context

Heart failure with preserved ejection fraction (HFpEF) typically presents with orthopnea, dyspnea, edema, and often subtle signs like an S3 or elevated JVP—despite a normal EF (>50%). Diagnosing it requires nuance, and ruling out other causes of dyspnea is key.

🧪 Rule Out First

Before calling it HFpEF, think differentials:

• Anemia
• Cirrhosis
• COPD exacerbation
• Renal failure
• NSAID-induced fluid overload
• Medication effects

Get a BNP (>100) or pro-BNP (>300), but remember these can be falsely low in obesity.

🔍 Look for Etiology

• Consider amyloidosis (found in 1 in 8 HFpEF cases)
• Assess for NSAID use, excessive dietary sodium/alcohol
• Be alert around holidays—fluid/salt overload is real!

🚩 Inciting Factors

• High-sodium and high-alcohol meals
• Holiday binges (Super Bowl, Christmas, Thanksgiving)
• Poor adherence to fluid restriction or diuretics

💊 Medications for HFpEF: Shelved Smartly

Top Shelf:

• SGLT2 Inhibitors (dapagliflozin, empagliflozin)
  • Class-wide effect
  • First-line for HFpEF with NYHA II–IV symptoms
• Finerenone
  • New on the scene
  • Especially promising in patients with diabetic kidney disease

Lower Shelf:

• Spironolactone
  • Evidence from the controversial TOPCAT trial
  • Use with caution; monitor K+ and renal function
• Sacubitril/Valsartan (ARNI)
  • Class IIb recommendation
  • Stronger benefit in women and men with EF <55–60%
  • Limited by high cost
• Candesartan
  • A viable option for those who can't afford ARNI
• Diuretics
  • Not disease-modifying but essential for symptom relief in volume-overloaded patients

⚠️ Clinical Considerations

• HFpEF is complex with limited effective therapies
• Many benefits are modest, but SGLT2 inhibitors stand out
• Etiology and lifestyle often drive exacerbations—address these too

🧩 Clinical Takeaway

Treating HFpEF is less about one miracle drug and more about combining modestly effective meds with personalized care. Always rule out other causes, explore etiologies like amyloidosis, and be mindful of inciting factors—especially around festive seasons.

SGLT2s lead the pharmacologic pack, but cost, side effects, and patient-specific factors still dictate the best plan. There's progress—but the heart of HFpEF still holds a few secrets.

🧠 Hidden epidemic:

50–70% of premenopausal women have iron deficiency.

Also common in CKD, GI bleeding, chronic disease.

🔍 Diagnosis Pearls:

Ferritin cutoff: <30 ng/mL (not 20!) for iron deficiency.

RLS patients: target ferritin >75.

Consider retic count: low = underproduction; high = bleeding/hemolysis.

💊 Treatment Tips:

Oral iron: ferrous sulfate preferred; daily dosing > TID.

Take with meat or vitamin C, avoid calcium or tea.

Alternate-day dosing may reduce GI side effects (but tricky compliance).

IV iron if oral not tolerated or patient is inflamed.

🧩 Clinical Takeaway:

Check for functional iron deficiency in inflammatory states.

Choose IV formulations based on cost, availability, and dosing frequency.

🧠 Clinical Problem:

HFpEF (Heart Failure with Preserved EF) has lacked effective, proven therapies.

Finerenone (non-steroidal MRA) offers new hope.

🧪 FINEARTS-HF Trial:

6,000+ patients with EF ≥40%, followed for ~32 months.

Compared Finerenone vs placebo.

📈 Results:

↓ Heart failure hospitalization significantly.

No significant reduction in CV mortality.

Hyperkalemia: 9.7% (Finerenone) vs 4.2% (Placebo).

🧩 Clinical Takeaway:

May offer benefit for HFpEF — especially if SGLT2i also used.

Expensive; Spironolactone may be a lower-cost alternative with similar benefit.

Important addition to the limited HFpEF toolbox.

🧠 Clinical Context

Fever is known to be associated with worse neurologic outcomes in stroke, both ischemic and hemorrhagic. Intuitively, preventing fever seems like a slam-dunk goal, right? This study took that theory to trial, literally.

🧪 Study Highlights: The INTREPID Trial

• Design: Open-label, randomized controlled trial with blinded outcome assessment
• Setting: 43 ICUs across 7 countries
• Participants: 686 critically ill stroke patients (254 ischemic, 223 ICH, 200 SAH)
• Intervention:
  • Fever prevention group: Surface cooling via automated gel pads, targeted at 37.0°C
  • Standard care group: Fever treatment only when temps hit ≥38.0°C
• Duration: Cooling maintained for 14 days or until ICU discharge

📈 Outcomes

• Primary:
  • Fever burden significantly reduced in the cooling group: 0.37 vs 0.73 °C-hour (P < .001)
  • Greatest fever reduction seen in ICH and SAH subtypes
• Secondary (Functional):
  • No difference in 3-month Modified Rankin Scale (mRS median = 4 in both groups)
  • Odds ratio for favorable shift: 1.09 (P = .54) — not statistically significant
• Adverse Events:
  • Higher total AEs in the cooling group (82% vs 76%)
  • Similar rates of infections, cardiac, and respiratory complications

⚠️ Caveats

• Trial halted early due to futility in primary functional outcome
• No significant improvement in functional recovery
• Fever control alone may not be enough — context and patient-specific variables likely matter

🧩 Clinical Takeaway

Cooling blankets do reduce fever after stroke, but don’t translate to better outcomes. Despite intuitive appeal and clear thermal control, the mRS at 3 months didn’t budge.

🏛️ Functional recovery from stroke remains complex. It's not just about temperature — we may need to refine who benefits and how we target them. More nuanced strategies are still needed.

🧠 Clinical Myth:

“Delay levodopa to delay motor complications.”

🧪 LEAP Trial (Levodopa in Early Parkinson’s):

Compared early start vs 40-week delayed start.

5-year follow-up showed no difference in motor fluctuations or dyskinesia.

📈 Key Outcomes:

Early levodopa = better function earlier, no long-term harm.

Wearing off effect was similar in both groups.

🧩 Clinical Takeaway:

Don’t hold back levodopa if patient is symptomatic.

Starting early improves quality of life without hastening decline.

Personalize the approach — don’t delay just for dogma.

🧠 Clinical Question:

Are we overtreating bloodstream infections with 14-day regimens?

🧪 Study Overview:

Multicenter RCT in ICU/inpatient settings (7 vs 14 days of antibiotics).

Excluded: Immunosuppressed, endocarditis, Staph aureus, and infections needing longer therapy.

📈 Findings:

No difference in 90-day mortality or relapse.

More C. diff and drug reactions in the 14-day group.

🧩 Clinical Pearls:

7 days is sufficient for most uncomplicated bacteremia.

Reserve 14+ days for Staph aureus, endocarditis, or deep-seated infections.

Fewer days = lower risk, lower cost, faster discharge.

🧠 Clinical Context:

Historically, breast cancer treatment has included radical mastectomies and full axillary dissections.

New data supports less invasive approaches for specific low-risk populations.

🧪 The SOUND Trial (and similar studies):

T1–T2 tumors (≤5 cm), clinically node-negative, ER+.

Compared no axillary surgery vs sentinel lymph node biopsy.

No difference in outcomes, but significantly less pain, lymphedema, and improved arm mobility in the non-surgical group.

🧩 Clinical Takeaway:

In selected ER+ patients with negative axillary imaging, sentinel lymph node biopsy may be safely omitted.

Shifts the focus to preserving quality of life without compromising survival.

The art of modern oncology = doing less, better.

🧠 Clinical Background:

Inflammation plays a big role in atherothrombosis.

Colchicine — an old gout drug — shows promise in CV risk reduction.

🧪 COLCOT Trial:

Colchicine 0.5 mg daily post-MI.

Greatest benefit in patients with type 2 diabetes.

📈 Outcomes:

Reduced MACE (MI, stroke, death) in diabetics.

Adverse Effects: Nausea, diarrhea, ↑ risk of pneumonia (unclear why).

🧩 Clinical Takeaway:

Consider colchicine in diabetics post-MI or with recurrent ACS.

Cheap, oral, and anti-inflammatory — a new use for an old drug.

🧠 Clinical Context:

Hypertrophic obstructive cardiomyopathy (HOCM): Genetic disorder causing LVOT obstruction.

Traditionally managed with BBs, CCBs, disopyramide… or surgery.

💊 Drug: Mavacamten (Cardiac Myosin Inhibitor)

Targets sarcomeric hypercontractility directly.

FDA approved for NYHA Class II–III obstructive HCM.

🧪 EXPLORER-HCM Trial:

62-week follow-up:

↓ LVOT gradient (resting & post-exercise).

Improved NYHA class.

↑ Peak oxygen consumption (VO₂).

⚠️ Key Considerations:

Follow-up echocardiograms required — risk of LVEF drop.

Avoid negative inotropes.

Can worsen HF if EF <55%.

🧩 Clinical Takeaway:

First disease-modifying med for obstructive HCM.

Exercise no longer strictly off-limits — patients should be supervised and tailored.

If surgery is needed, refer to high-volume HCM centers only.

🧠 Clinical Problem:

Behavioral disturbances in Alzheimer’s are notoriously hard to treat.

Guidelines tell us: “Don’t use antipsychotics” — but what do you do at 2AM when Nana's throwing punches?

💊 Study Overview:

345 patients, moderate-severe Alzheimer’s + aggressive agitation.

Brexpiprazole 2–3 mg daily vs placebo.

Dosing didn’t differ much in effect.

📈 Outcomes:

Significant reduction in agitation inventory scores in brexpiprazole group.

Well tolerated; most common side effect: headache (7%).

⚠️ Caveats:

Costly medication.

Atypical antipsychotic — still carries black box warning for mortality in dementia.

🧩 Clinical Takeaway:

Brexpiprazole may offer a much-needed option in patients with severe behavioral disturbances.

Not for mild sundowning — reserve for safety-critical scenarios.

Discuss risks/benefits carefully with family or POA.

🧠 Clinical Question:

What's the optimal hemoglobin threshold for transfusion post-MI?

Old dogma: “Keep Hgb >10”.

New data: Less might be just as safe.

🧪 The MINT Trial (Myocardial Ischemia & Transfusion):

Compared liberal (Hgb <10) vs restrictive (Hgb <8) transfusion strategies.

Lower 30-day recurrent MI or cardiac death seen with Hgb ≥10 approach.

But... secondary analysis showed no major difference between 9 vs 10.

⚠️ Risks of Transfusion:

Volume overload (TACO).

Hemolytic and allergic reactions.

Cost and hospital stay increase.

🧩 Clinical Takeaway:

Consider transfusing at Hgb 9–10 in post-MI, particularly if symptoms or hemodynamics justify it.

Be cautious, but not rigid — individualize based on patient condition.

🧠 Clinical Context:

For patients who absolutely cannot tolerate statins — despite trying multiple options or experiencing severe side effects.

Reminder: Always try multiple statins first (different types, dosages, timing) before declaring “statin intolerance.”

💊 What is Bempedoic Acid?

Non-statin oral agent, works upstream of HMG-CoA reductase.

Liver-activated – avoids muscle toxicity seen in statins.

First oral non-statin to reduce MACE-4 endpoints.

📈 Clinical Impact:

LDL-C reduction: 20–25%.

Cardiovascular events:

23% ↓ in MI.

19% ↓ in coronary revascularization.

⚠️ Adverse Effects:

Gout, gallstones, elevated transaminases.

Avoid if history of uric acid disorders.

🧩 Clinical Takeaway:

Great adjunct to maximally tolerated statin or for rare, true statin-intolerant patients.

Not first-line — statins remain king, with 40–50% LDL reduction.

🧠 Clinical Context:

BBs have been MI standard since the thrombolysis era.

But do they still help when patients get PCI, statins, and ACEs?

🧪 Two Major Studies:

Swedish Registry Study:

Post-MI patients with preserved EF.

All received PCI + standard meds.

BB vs no BB: No difference in death or recurrent MI.

French Study (New England Journal):

MI 2.9 years prior, preserved EF.

BB continuation vs discontinuation:

Slight reduction in composite endpoint (death/MI/stroke/hospitalization).

Driven mostly by fewer hospitalizations (17% vs 19%).

⚖️ Pros and Cons of Beta Blockers:

✅ Pro: Cardioprotection, arrhythmia prevention.

❌ Con: Depression, fatigue, ED, bradycardia.

BBs aren’t benign — side effects matter to patients.

🧩 Clinical Pearls:

If EF is normal and patient is stable post-MI: Reassess need for long-term BB.

Ongoing trials will help guide “de-prescription” thresholds.

Don't forget individualized care: patient preference, arrhythmia risk, BP goals.

🧠 Clinical Context:

Episodic migraines (<15 days/month) that don’t respond to traditional preventives.

Patients often fail beta blockers, AEDs, TCAs, CCBs — need new options.

🧪 Study – RCT on Atogepant:

315 patients, mostly women, who failed ≥2 oral preventives.

Randomized to atogepant 60 mg daily vs placebo.

Follow-up: 3 months.

📈 Outcomes:

≥50% migraine reduction:

51% in atogepant group vs 18% placebo.

Most common side effect: Constipation (10% vs 3%).

💊 Mechanism:

CGRP receptor antagonist – blocks calcitonin gene-related peptide, a known migraine mediator.

🧩 Clinical Application:

Strong option for treatment-refractory episodic migraine.

Easier than injectables; potential for earlier use in future guidelines.

🧠 Clinical Context:

Blood pressure errors due to bad positioning = misdiagnosis and mistreatment.

We often blame the drug, when the data was flawed to begin with.

🧪 Study Highlights:

104 patients tested with 3 positions:

Hand in lap: BP falsely elevated by 4 mmHg.

Arm unsupported: +6 mmHg (most common real-world scenario).

Arm supported at heart level: accurate.

✅ Gold Standard Technique:

Seated, feet flat on floor, arm supported at heart level, relaxed.

No caffeine, nicotine, or exercise 30 minutes prior.

No talking. Cuff on bare skin, correct size (80% of upper arm).

Wait 5 minutes pre-reading. Repeat if >5 mmHg difference.

⚠️ Clinical Consequences:

Misclassified HTN → overtreatment, hypotension, dizziness.

Standardize BP checks in your clinic—“militant consistency” matters.

🧠 Clinical Context:

Nursing home residents are fragile fall-prone patients.

Starting a new antihypertensive could trigger orthostasis → serious fractures.

🧪 Study – VA Nursing Home Cohort:

13,000+ residents tracked from 2006–2019, mean age ~78.

Examined fracture risk 30 days after starting an antihypertensive.

Fractures studied: Pelvic, hip (requiring surgery), humerus, radius, ulna.

📈 Outcomes:

New antihypertensive initiated → 4.5 serious falls per 100 person-years.

No med change → 2.2 events per 100 person-years.

That’s >2x risk with a new med.

🩺 Clinical Tips:

Orthostatic BP check should be done 3–6 minutes after standing (not just 1–2 min).

Median best time: 4.5 minutes.

Use shared decision-making: Is the BP goal worth a possible hip fracture?

Consider deprescribing or "start low, go slow" approach in long-term care.

🧠 Clinical Context:

Subclinical atrial fibrillation = asymptomatic episodes of AF detected by implantable monitors or Holters, lasting 6 minutes to 24 hours.

Big Question: Should we anticoagulate these patients?

🧪 Study Highlights – ARTESiA Trial:

Design: 4,012 patients (mean age 76.8), randomized to apixaban 5 mg BID vs ASA 81 mg daily.

Inclusion: Age >55 with or without history of stroke/TIA; device-confirmed subclinical AF.

📈 Outcomes:

Primary endpoint: Stroke or systemic embolism.

With prior stroke/TIA:

Apixaban significantly reduced events: 1.2% vs 3.4% annually.

Without prior stroke/TIA:

No significant difference: 0.74% (apixaban) vs 1.07% (ASA).

🧩 Clinical Pearls:

Don’t reflexively anticoagulate all device-detected AF — stratify by stroke history.

Consider CHA₂DS₂-VASc, but more importantly, patient-specific functional risk.

Use the Modified Rankin Scale to contextualize why stroke prevention matters:

0 = no symptoms, 5 = severe disability, 6 = death.

Patient framing tip: “If a stroke leaves you unable to walk, speak, or go to the bathroom independently, would that be worth preventing with a pill?”